Anti –programmed death ligand 1 immunotherapies in cancer patients with pre-existing systemic sclerosis: A postmarketed phase IV safety assessment study

This study investigated the tolerability and efficacy of anti –programmed death ligand 1 (PD (L)1) immunotherapies in patients with pre-existing SSc.
Source: European Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Original Research Source Type: research